Objectif
TransQST will develop a Quantitative Systems Toxicology (QST) approach, employing pre-existing data where possible, in order to yield new mechanistic insight into drug-induced toxicity. A central tenet of our programme will be to ensure the human physiological and pharmacological relevance of any test system that has been (or will be) used for generating the input data for modelling. By adopting this approach, we will be able to accurately interpret what happens when test systems are perturbed by drug exposure, and ensure translatability of modelling tools. Mechanistic translational biomarkers are a core aspect of our approach and will be applied in parallel with evidence for understanding how to develop, model and apply such biomarkers in a QST setting. The project is structured in 8 work packages to provide the following outcomes: curate the best available experimental data suitable for modelling adverse drug reactions; provide fit-for-purpose QST models that will address key toxicity measures for liver, kidney, heart and GI-tract; provide quantitative risk assessment for off-target toxicity in man based on in vitro and in vivo models; provide a quantitative mechanistic read-across from species (in vivo and in vitro) currently used for the toxicological evaluation of a new drug; provide definition and applicability of the human physiological relevance of preclinical test systems; provide a battery of translational biomarkers that can be used for quantitative read-across from in vitro systems to man and which relate to intracellular pathways (and systems) relevant to drug toxicity. Led by the University of Liverpool, TransQST brings together 14 partners, characterized by their scientific rigour and proven track record. Collectively they will enable achievement of the goals of the call, thanks to their complementarity, proven ability to work together (and with EFPIA partners), and their understanding of how to ensure the relevance of QST to human biology.
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinepharmacology and pharmacydrug safety
- medical and health sciencesclinical medicinecardiologycardiovascular diseasescardiac arrhythmia
- medical and health sciencesbasic medicinepharmacology and pharmacyadverse drug reactions
- medical and health sciencesbasic medicinetoxicology
Mots‑clés
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
L69 7ZX Liverpool
Royaume-Uni
Voir sur la carte
Participants (23)
2311 EZ Leiden
Voir sur la carte
08003 Barcelona
Voir sur la carte
28006 Madrid
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
6200 MD Maastricht
Voir sur la carte
69117 Heidelberg
Voir sur la carte
OX1 2JD Oxford
Voir sur la carte
EC2Y 5EB London
Voir sur la carte
1010 Wien
Voir sur la carte
Participation terminée
52074 Aachen
Voir sur la carte
44139 Dortmund
Voir sur la carte
3512 KC Utrecht
Voir sur la carte
3015 GD Rotterdam
Voir sur la carte
65205 Wiesbaden
Voir sur la carte
RG21 4FA Basingstoke
Voir sur la carte
94250 GENTILLY
Voir sur la carte
151 85 Sodertaelje
Voir sur la carte
TW89GS Brentford
Voir sur la carte
92284 Courbevoie
Voir sur la carte
2340 Beerse
Voir sur la carte
02200 Espoo
Voir sur la carte
55218 Ingelheim
Voir sur la carte
69120 Heidelberg
Voir sur la carte
W2 6BD London
Voir sur la carte